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Background: Pregnant women remain are at an increased risk of malaria with primigravidae being at the highest
risk. Genetic polymorphism of the Fc receptor IIa for immunologlobulin (Ig) G (FcγRIIa) determines IgG subclass
binding. Protection against pregnancy-associated malaria (PAM) is associated with the production of IgG specific for
apical membrane antigen-1 (AMA-1). The present study was undertaken to examine the relationship between
specific IgG/IgG subclasses and malaria infection. The second aim of the study is to examine the association
between FcγRIIa R/H131 polymorphism in correlation with specific anti-malarial IgG antibodies of AMA-1
distribution and asymptomatic malaria infection among Saudi women living in the southern part of Saudi Arabia.
Methods: One hundred and twenty pregnant women living in an area of meso-endemic Plasmodium falciparum
malaria infection were consecutively enrolled onto the study. These pregnant women were asymptomatic and
attending routine antenatal clinics. The levels of plasma antibodies (IgG and subclasses AMA-1) were measured
using indirect enzyme-linked immunosorbent assays (ELISA). Genotyping of FcγRIIa-R/H131 dimorphism was
performed using gene-specific polymerase chain reaction (PCR) amplification with allele-specific restriction enzyme
digestion (BstU1) of the PCR product.
Results: A total of sixty-two (52%) pregnant women was diagnosed with asymptomatic malarial infection (ASM)
compared with 58 (48%) malaria free controls (MFC). In the ASM group, there were high levels of anti-malarial IgG1
and IgG3, when compared to MFC (P value <0.001, respectively). The FcγRIIa-R/R131 genotype and R131 were
found to be statistically significantly more prevalent in the ASM group when compared to the MFC group [55% for
ASM versus 12% for MFC, odds ratio (OR) 5.62, 95% confidence interval (CI)= (2.03- 15.58), P value= 0.001]. However,
the H/H131 genotype showed statistically significant association with MFC [14% for ASM versus 50% for MFC, OR
(0.36), 95% CI= (0.14- 0.95), P value= 0.03].
Conclusions: The study revealed that the ASM patients had higher anti-malarial IgG and IgG subclasses antibody
levels when compared to the MFC. The FcγRIIa-R/R131 genotype and R131 allele were found to be statistically
prevalent in the ASM when compared to the MFC group. The individuals carrying H/H131 were consistently
associated with higher levels of anti-malarial IgG subclasses.
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Malaria remains a devastating global health problem.
The Arabian Peninsula lies at the fringes of malaria en-
demicity. Control efforts have successfully brought local
transmission to a halt in many parts, with the exception
of southern Saudi Arabia. In areas of intense parasite
transmission, Plasmodium falciparum malaria is largely
a childhood disease due to the gradual achievement of
protective immunity. Each year, more than 125 million
pregnant women are at risk of malaria infection with
devastating consequences for the newborn and first and
second time mothers [1]. In highly endemic settings, up
to 50% of low birth weight (LBW) deliveries can be at-
tributed to malaria in pregnancy. Pregnancy-associated
malaria (PAM), which is characterized by accumulation
of infected red blood cells (iRBCs) in the placental
intervillous space [2-4], is a major cause of LBW and
maternal anaemia in areas of endemic malaria transmis-
sion [5-7]. The pathogenesis of PAM and its association
with adverse pregnancy outcome [8,9], such as intraute-
rine growth restriction and LBW is not well understood.
One hypothesis for the adverse pregnancy outcome is
the impairment in nutrient transport to the foetus [10],
with possible effects on growth regulating hormones
[11], and trophoblast invasion [12]. Previous in vivo
studies showed the absence of adhesiveness to other re-
ceptor molecules mediating adhesion to receptors lo-
cated only in placental tissue [2]. This may explain the
susceptibility to malaria in otherwise clinically immune
women at the time of their first pregnancy [4].
Antibody-dependent cellular mechanisms are thought
to be central in the elimination of the parasite [13-16],
and severe malaria is associated with increased pro-
inflammatory immune response [17]. Immunoglobulin
G1 (IgG1) and IgG3 are considered cytophilic and pro-
tective against P. falciparum. While low levels of IgG4
was thought to be relatively associated with protective
mechanisms [15]. FcγRIIa exhibits a genetic polymor-
phism, FcγRIIa-R/H131 which codes for different capaci-
ties of IgG binding and phagocytosis [18-22]. Furthermore,
IgG2, which binds the H131 allelic form of FcγRIIa, may
be involved in human resistance to malarial infection
[15,18,20]. A defence mechanism requiring the association
of antigen bound IgG antibodies with FcγRs on monocytes
is thought to play an important role in protecting immune
African adults from malaria [18-20,23,24]. Only a few
studies on FcγRIIa- R/H 131 polymorphisms in relation to
malaria have been performed. A study in Western Kenya
showed that the FcγRIIa 131H/H genotype was associ-
ated with enhanced susceptibility to placental malaria in
HIV-positive, but not in HIV-negative women [25].
Hypothetically, immune responses against malaria can
be distinguished into long- and short-term responses.
Long-term response being broad and represented bypre-existing immunity, which may or may not be pro-
tective [26,27]. In contrast, the short-term immunity fol-
lows acute infection. Antibodies measured during acute
infection or convalescence represent both boosted pre-
existing and short-term immunity. However, it remains
an open question as to whether a low level of malaria
transmission is maintained throughout the dry season
when clinical disease is absent. Furthermore, little is
known about the relationship to the seasonal patterns of
malaria transmission.
The present study was undertaken to examine the re-
lationship between specific IgG/IgG subclasses and ma-
laria infection. The second aim of the study is to examine
the association between FcγRIIa R/H131 polymorphism
in correlation with specific anti-malarial IgG antibodies
of AMA-1 distribution and asymptomatic malaria in-




This study was conducted in Jazan city in the southern
Kingdom of Saudi Arabia (KSA), during the dry season,
March to August 2012 (estimated population, 157,536
according to the 2010 census). The annual rainfall (be-
tween June and September) fluctuates from one year to
another, and for that reason the incidence of malaria is
markedly unstable. The uniqueness of this epidemio-
logical setting is due to marked seasonality of low to
moderate transmission of malaria. Whereas more than
90% of annual malaria incidence occurs between Octo-
ber and January; it is rare for a patient to develop more
than one to two episodes of malaria during the season.
Thus, it is easier to trace the immunological conse-
quences of a single infection without interference of a
superimposed infection. However, few sporadic cases of
malaria may occur throughout the year.
Study design and patient enrolment
A prospective cohort (cross-sectional) study was con-
ducted in pregnant women attending routine antenatal
clinics in King Fahad Specialist Hospital in Jazan
(KFSHJ), without a clinical diagnosis of malaria. Patients
with asymptomatic malaria are those without any of the
classical symptoms of malaria infection as described by
the WHO [28]. Patients were recruited after written in-
formed consent was gained from them. Blood samples
were taken for confirmation of malaria. Once patients
were found to be positive for malaria, treatment was of-
fered. Patients with asymptomatic malaria in their first
trimester of pregnancy received quinine (20 mg/kg loa-
ding dose) plus clindamycine for seven days. Patients
in their second and third trimesters received standard
anti-malarial combination therapy (ACT). Standard ACT
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single dose of sulphadoxine-pyrimethamine (25 mg/kg)
given on day 0 [29-31]. All patients were reviewed by the
study gynaecologist to confirm that there were no other
co-infections apart from malaria. No one from the study
groups was found to be HIV positive. All patients with
other infectious diseases were excluded from the study.
To control for the ethnicity factor, all the patients were
from a Saudi background. The Saudi populations are ori-
ginally Arab tribes living in the Arabian Peninsula for
more than 1,434 years.
The study was reviewed and approved by the Ethics
Review Committee in the College of Medicine at Taif
University.
Sample collection
Before pharmacological treatment was started, 50 μL of
blood were collected on filter paper (Schleicher &
Schuell; n° 903TM) for DNA amplification, parasite
detection and measurement of immunoglobulin. One ml
of venous blood sample was collected into EDTA
VacutainerW tubes (Becton Dickinson, Meylan, France)
for parasite measurements. This was put into thick and
thin blood smears obtained at the time of collection,
which were then stained with Giemsa.
Serum and DNA extraction
Serum extraction was eluted from a 50 μl blood drop onto
filter-paper samples, as described previously [32,33].
DNA was extracted from a 50 μl blood drop onto filter
paper with QIAampW DNA Mini Kit (Qiagen, Hamburg,
Germany), and re-suspended in 150 μl of TEB buffer [20].
Parasite genotype
Five μl of DNA samples were used to detect the P. falciparum
malaria parasite using a polymerase chain reaction (PCR),
targeting for ama-1_3D7 gene as described previously
[34,35]. For the negative controls, we used blood samples
collected from Swedish individuals who were never ex-
posed to P. falciparum malaria parasites. For the positive
controls, we used blood samples collected from Sudanese
individuals who have been exposed to P. falciparum
malaria parasites in the past.
Enzyme-linked immunosorbent assays (ELISA)
IgG antibody was measured against the recombinant
protein apical membrane antigen-1 (AMA-1), which
has an N-terminal hexa-His tag, that is expressed in
Escherichia coli and refolded in vitro. The expression
and purification of these proteins was described earlier
in [36,37]. The levels of serum antibodies (IgG total and
subclasses) to malaria antigen (AMA-1) was measured
using enzyme-linked immunosorbent assays (ELISA) as
previously described [19,38]. EIA/RIA plates (Costar,MA, USA) were coated with AMA-1 at 1 μg/mL. The
plates were incubated overnight at 4°C and then blocked
for two hours with 0.5% bovine serum albumin (BSA) di-
luted in carbonate-bicarbonate buffer (pH 9.6). Plasma
samples were diluted in incubation buffers (PBS + 0.5%
BSA), 1:1000 for IgG and 1:400 for IgG subclasses
(IgG1-4). Each sample was added in duplicates in the
ELISA plate and incubated for one hour at 37°C. The
plates were washed four times, and bound IgG anti-
bodies were detected with goat anti-human IgG-ALP
(1:2,000) (Mabtech, Nacka, Sweden). IgG subclasses
were analysed with their respective biotin conjugated
mouse anti-human subclass specific monoclonal anti-
bodies: mouse anti-human IgG1 1:1,000 (M15015, Clone
NL16, SkyBio, Bedfordshire, UK), mouse anti-human
IgG2 1:3,000 (555874, Pharmingen, Erembodegem,
Belgium), mouse anti-human IgG3 1:1,000 (MH 1532,
Caltag Laboratories, Paisley, UK) and mouse anti-human
IgG4 1:2,000 (B3648, Sigma, St. Louis, USA). Alkaline
phosphatase (ALP) conjugated streptavidin (Mabtech)
diluted 1:2,000 was added to detect bound antibodies of
IgG2-4, while ALP-conjugated to goat anti-mouse Ig
(Dakopatts, Glostrup, Denmark; 1:1,000) was used
for IgG1 antibodies, and colour was developed with
nitrophenyl phosphate (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany). The absorbance was read at 405 nm
using a VmaxTM Kinetic microplate reader (Molecular
Devices, Menlo Park, USA).Statistical analysis
Statistical analysis was performed by SPSS version 10.0
software for Windows (SPSSW, Inc, Chicago, IL, USA).
In this study, the antibody (IgG and IgG subclass) levels
were analysed using Kruskal-Wallis test (non paramet-
ric) and the P values were derived. With regards to the
risk of malaria infection during the pregnancy period,
P values were considered significant if < 0.05. Overall,
the 95% confidence intervals (CI) for odds ratio (OR)
that did not cross 1.00 were statistically significance. OR
above 1 represents values associated with the asympto-
matic malaria group while less than 1 represents the
malaria-free control group. To assess the association
between the FcγRIIa genotype and malaria infection
(dependent variable), logistic regression analysis was
preformed with age and pregnancy duration as con-
founding factors. The FcγRIIa- Arg/ His 131 group was
used as a reference in the analyses, as this is the geno-
type most prevalent in the human population [39]. The
comparison of allele frequency was performed using a
2 × 2 chi-square test. To assess the relationship between
the IgG (AMA-1) isotype levels and prevalence of para-
site density in asymptomatic malaria patients; we used
logistic regression analysis test.
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Characteristics of the study participants
A total of 120 pregnant women, were consecutively en-
rolled in the study and were classified into three groups
according to pregnancy duration. Group I: First tri-
mester [n=47 (39.2%); median age of 21 with a range
of (18–26) years] (Table 1). Group II: Second trimester
[n=33 (27.5%); median age of 22 with a range of (18–
26) years] (Table 1). Group III: Third trimester [n=40
(33.3%); median age of 23 with a range of (18–26) years]
(Table 1). Overall, there was statistical difference in the
median and range of mother's age in the pregnancy du-
ration P value= 0.046 (Table 1). A total of 58 women
(48%); median age of 22 with a range of 18–26 years,
were malaria parasite negative and had no clinical symp-
toms of malaria infection [malaria-free controls (MFC)].
A total of 62 women (52%); median age of 22 with a
range of 18–26 years were malaria parasite positive and
had no clinical symptoms of malaria infection [asymp-
tomatic malaria (ASM)]. In the ASM patients, the
median parasite density was 1,200 with a range of
250–2,000 parasite/μL). This is relatively low parasite
density according to the WHO criteria [28]. There were
no differences in age between the two study populations
(median age 22 years for ASM versus MFC; OR= 1.29,
95% CI= 0.63–2.68, P value 0.486). All women attending
the outpatient clinic at the time of enrolment were
assessed initially by microscopy of blood film, andTable 1 Characteristics of the study groups, median (range) f
regarding pregnancy duration
Study groups variables First trimester
Malaria-free control n=58 (48%) 13 (22.4%)
Asymptomatic Malaria n=62 (52%) 34 (54.8%)
FcγRIIa genotypes
R/R131 n=41 (%) 22 (53.7%)
R/H131 n=41 (%) 20 (48.8%)
H/H131 n=38 (%) 5 (13.2%)
FcγRIIa alleles
R 131 allele 0.68
H 131 allele 0.32
Median (range) for:
Age/years 21 (18–26)
Parasite density/μl 1600 (250–2000)
Specific antibody for AMA-1
IgG 1.28 (0.28- 6.04)
IgG1 0.59 (0.11- 21–95)
IgG2 0.04 (0.02- 5.64)
IgG3 0.52 (0.01- 37.94)
IgG4 0.02 (0.01- 2.62)subsequent confirmation by PCR as mentioned in the
parasite genotype section.
Relative risk to malaria infection with parasite density,
IgG and IgG subclasses in association with pregnancy
duration
The characteristics of the pregnant women are shown in
Table 1. The prevalence of malaria infection during the
pregnancy duration was statistically significant, overall
P value= <0.001 (Table 1). The pregnant women in the
first and second trimesters showed higher incidence of
malaria infection when compared with the pregnant
women in their third trimester, P value <0.001. With
regards to the prevalence of malaria infection in the first
and second trimester, there was no statistical difference
observed between the two groups P value= 0.253. There
was statistically significant difference in the median
parasite density of women in the third trimester com-
pared to the first and second, P value= 0.007 (Table 1).
Overall, there were statistical differences with FcγRIIa
genotype frequencies and pregnancy duration; P value
<0.001 (Table 1). Furthermore; the frequency of R131
allele was higher within the first and second trimesters
compared to women in the third trimester (Table 1).
However, the H131 allele was of a significantly higher
frequency in pregnant women during the third trimester
compared to women in the first or second trimesters
(Table 1). Overall, there was statistically significantor (age, parasite density, IgG and IgG subclasses)
Second trimester Third trimester P value
13 (22.4%) 32 (55.2%) <0.001
20 (32.3%) 8 (12.9%)
17 (41.5%) 2 (4.9%) <0.001
11 (26.8%) 10 (24.4%)
5 (13.2%) 28 (73.7%)
0.68 0.18 0.004
0.32 0.82
22 (18–26) 23 (18–26) 0.046
1400 (510–2000) 1050 (250–2000) 0.007
1.28 (0.50- 7.30) 2.76 (0.29- 6.90) 0.003
5.30 (0.16- 22.27) 5.43 (0.05- 32.89) 0.180
2.11 (0.02- 5.73) 2.16 (0.02- 6.10) 0.040
8.33 (0.12- 39.45) 8.39 (0.09- 46.00) 0.185
0.59 (0.01- 3.24) 0.61 (0.01- 2.01) 0.514
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duration within the study groups; P value 0.004 (Table 1).
The median level of IgG and IgG2 were statistically
different between groups within the pregnancy duration;
P value= 0.003 and 0.040 respectively (Table 1). How-
ever, no statistical differences were observed between
the median level of IgG1, IgG3 and IgG4 and the three
trimesters (Table 1). In addition, the median levels of
anti-malarial IgG and IgG subclasses were higher in the
third trimester than the first trimester (Table 1).
Patterns of antibody isotype in relation to relative risk of
malaria infection Plasmodium falciparum-specific IgG and
IgG subclasses
For anti-malarial IgG1 and IgG3, the ASM group
showed very high levels compared to the MFC (P value
<0.001, respectively) (Table 2). For the anti-malarial IgG
antibody and IgG subclasses, the ASM showed signifi-
cantly higher levels of IgG, IgG2 and IgG4 (P value
0.001, respectively) (Table 2). The most dominant sub-
class amongst the anti-malarial antibodies was IgG3,
followed by IgG1, IgG2 and IgG4 in both study groups.
Correlation of IgG subclass levels in relative risk of
Plasmodium falciparum parasite density
The sixty-two patients diagnosed with ASM were inves-
tigated to determine whether the anti-AMA-1 IgG levels
were associated with P. falciparum parasite density.
Interestingly, there was statistically significant association
between higher levels of IgG, cytophilic IgG1 and IgG3
subclass antibodies and a reduction in parasite density
(lower than1,000 parasites/μL). The OR for IgG = 0.13; 95%
CI: (0.02- 0.71) and P value = 0.005. The OR for IgG1 =
0.13; 95% CI: (0.03- 0.59) and P value = 0.008]. The OR for
IgG3 = 0.5; 95% CI: (0.14- 1.74) and P value = 0.034]
(Table 3). No significant associations were observed for
non-cytophilic IgG subclasses and the parasite density
(IgG2 and IgG4) (Table 3).
FcγRIIa-R/H 131 genotype and allele frequency in relation
to asymptomatic malaria
All subjects within the two study groups were genotyped
for the G494A single nucleotide polymorphism (R131H)
in the FcγRIIa gene (rs1801274). Both allele and genotypeTable 2 Comparison between specific antibody (AMA-1) in as
Specific Ig
antibodies
Median (Range) of the anti-
(MFC) n= 58 (48%)
IgG 0.90 (0.28- 1.90)
IgG1 0.20 (0.05- 1.58)
IgG2 0.41 (0.02- 0.16)
IgG3 0.48 (0.01- 0.65)
IgG4 0.01 (0.01- 0.56)frequencies were found to be in Hardy-Weinberg equilib-
rium (P value= 0.813) (Table 4). R/R131 genotype was
dominant amongst ASM patients compared to MFC
(55% for R/R versus 31% for R/H genotypes; unadjusted
OR= 5.62; 95% CI (2.03-15.58), P value= 0.001 and ad-
justed OR= 5.11; 95% CI (1.74- 15.00), P value= 0.003)
(Tables 4 and 5). The homozygote H/H131 genotypes was
found to be statistically significant at higher frequency in
MFC individuals compared to ASM patients [50% for
H/H versus 40% for R/H genotypes; unadjusted OR= 0.36;
95% CI (0.14- 0.95), P value = 0.03] (Tables 4 and 5). Fol-
lowing the adjustment of the OR for pregnancy duration
and age of pregnant women, there appears to be no statis-
tical significance [adjusted OR= 0.75; 95% CI (0.26- 2.62),
P value= 0.75] (Tables 4 and 5). With regard to FcγRIIa
allele frequencies, there were significant differences between
the ASM and MFC individuals, the R131 allele being
more frequent than the H131 allele amongst ASM pa-
tients (0.70 versus 0.30), OR 3.31, 95% CI (1.59–6.56),
P <0.001 (Table 4).
Analysis of anti-malarial antibodies in relation to FcγRIIa
genotype
The distribution of FcγRIIa genotype and IgG subclass
profile in the subject groups were analysed. Kruskal-
Wallis (nonparametric) test showed that IgG3 antibodies
specific to AMA-1 malarial antigen were associated with
individuals carrying the R/R131 genotype than H/H131
genotype in the ASM group (P value <0.001) (Table 6).
High levels of anti-malarial IgG1, IgG2 and IgG4 anti-
bodies specific to AMA-1 malarial antigen, were associ-
ated with individuals carrying the R/R131 genotype than
the H/H131 genotype in the ASM group (P value =0.021,
0.021 and 0.006 respectively) (Table 6).
Discussion
Despite the importance of malaria in pregnancy, this may
be the first report on the immunology of P. falciparum in
pregnant Saudi Women. This report investigated the rela-
tionship between specific IgG, IgG subclasses (AMA-1)
antibodies, and FcγRIIa R/H131 polymorphism in asso-
ciation with asymptomatic malaria infection among
Saudi women living in southern KSA. The risk of ma-
ternal infection was highest during the first and secondymptomatic malaria patients and malaria free controls
malarial (AMA-1) antibodies P
value(ASM) n= 62 (52%)
3.36 (0.80- 7.30) 0.001
6.73 (4.90- 32.89) <0.001
2.67 (1.84- 6.10) 0.001
11.32 (7.52- 46.00) <0.001
0.75 (0.01- 3.24) 0.001
Table 3 Logistic regression analysis of the IgG (AMA-1) isotypes levels and prevalence of parasite density in
asymptomatic malaria patients
Parasite density Unadjusted OR; (95% CI) P value
IgG Higher than 1500 parasite/μl 11.61; (2.12- 13.73) 0.018
1000- 1500 parasite/μl 1
Lower than 1000 parasite/μl 0.13; (0.02-0.71) 0.005
IgG1 Higher than 1500 parasite/μl 1.68; (0.25-11.23) 0.595
1000- 1500 parasite/μl 1
Lower than 1000 parasite/μl 0.13; (0.03- 0.59) 0.008
IgG2 Higher than 1500 parasite/μl 2.00; (0.41- 9.78) 0.370
1000- 1500 parasite/μl 1
Lower than 1000 parasite/μl 0.54; (0.14- 2.07) 0.392
IgG3 Higher than 1500 parasite/μl 6.33; (1.15- 15.01) 0.275
1000- 1500 parasite/μl 1
Lower than 1000 parasite/μl 0.500; (0.14- 1.74) 0.034
IgG4 Higher than 1500 parasite/μl 3.69; (0.82- 6.66) 0.371
1000- 1500 parasite/μl 1
Lower than 1000 parasite/μl 1.85; (0.48- 7.06) 0.089
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and CD25+ regulatory T cells, which increase during the
third trimester, modulate the immune response [40]. The
levels of CD4+ and CD25+ regulatory T cells gradually
returns to normal level after pregnancy, thus reflecting
the pattern of increased incidence of malaria during the
first and second trimesters [40]. Specific Th1–type im-
mune responses are pivotal for successful immunity to
malaria. These are altered during pregnancy, which
might diminish the ability to control new infections and
asymptomatic parasitaemia. As a consequence, pregnant
women are put at an increased risk of the development
of malaria [41].
When assessing the relationship between specific IgG,
IgG subclasses (AMA-1) antibodies and pregnancy du-
ration, it appears that there is a significant difference in
IgG and IgG2 between the study groups and the du-
ration of pregnancy. Furthermore, the levels of anti-
malarial IgG and IgG subclasses were higher in the third
trimester than the second and first trimesters. ThisTable 4 Distribution of the FcγRIIa-131 and allele frequency i
malaria free control
FcγRIIa genotypes Malaria-free control n=58 (48%) Asymp
R/R131 n=41 7 (12%)
R/H131 n=41 22 (40%)
H/H131 n=38 29 (50%)
Alleles frequency*
R 131 allele 0.31
H 131 allele 0.69
* OR = 3.31, 95% CI (1.59–6.56); P value <0.001.finding may offer an explanation to the lower prevalence
of malaria infection in the third trimester when com-
pared to the first and second. In support of this finding,
a previous study in Mali by Dicko et al. reported the first
trimester as the main risk period for malaria infection
[42]. Furthermore, a recent study in Sudan showed that
pregnant women in their second trimester were more
susceptible to malaria infection [43].
The current study showed accumulative association of
high levels of IgG and IgG subclass antibodies with
ASM patients. In support of this finding, a previous co-
hort study in Gabon showed that pregnant women who
had malaria infection had higher levels of specific IgG of
variant surface antigens (VSA) antibody compared to
women who had no malaria infection [44].
The correlation of anti-malarial IgG, IgG subclass anti-
bodies and malaria infection showed that the serum
levels of IgG1 and IgG3 subclass antibodies were
found to be higher than IgG2 and IgG4 antibodies, for
P. falciparum blood-stage AMA-1 antigen. The cytophilicn relation to asymptomatic malaria compared with






Table 5 Logistic regression analysis of the FcγRIIa-131 in relation to asymptomatic malaria compared with malaria free
control
FcγRIIa genotypes Unadjusted OR; (95% CI) and P value Adjusted* OR; (95% CI) and P value
R/R 131 5.62; (2.03- 15.58), 0.001 5.11; (1.74- 15.00), 0.003
H/R 131 1 1
H/H 131 0.36; (0.14- 0.95), 0.03 0.75; (0.26- 2.62), 0.75
* Adjustment of OR was performed for pregnancy duration and age.
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strumental in protective immunity, while non-cytophilic
antibodies against the same epitopes may block the pro-
tective activity of cytophilic ones [16,23,45]. Several sero-
epidemiological studies have supported these findings by
indicating an association between protection from malarial
infection with antibodies of IgG1 and IgG3 subclasses
[20,45,46]. Furthermore, when comparing the antibody
levels between the ASM and malaria free controls, the
ASM showed significantly higher levels of IgG2 and IgG4
antibodies reactive to AMA-1. Previous studies from
different endemic areas in Africa, showed a correlation
between the severity of malarial infection and high circu-
lating levels of IgG2 [15,20,47].
When assessing the relationship between anti-malarial
IgG, IgG subclass antibodies and the risk of parasite
density, there were higher levels of anti-malaria AMA-1
antibody IgG, IgG1 and IgG3. This may have played a
crucial role in parasite reduction. The suggested mech-
anism by which these subclasses are protective involves
their binding to the FcRs on monocytes, leading to anti-
body dependent cell mediated inhibition of parasite rep-
lication [23,45]. This is supported by the results from
this study, since the two most predominant IgG sub-
classes, are IgG1 followed by IgG3. All of the above
mechanisms may have affected the parasite density and,
therefore, leading to infected patients without clinical
symptoms.
The importance of FcγRIIa with regards to malaria
comes from its role as a link between the humoral andTable 6 Correlations between the median values of IgG (AMA






Malaria free controls R/R 0.60 (0.50- 0.80) 0.62 (0.1
R/H 0.95 (0.28- 1.90) 0.17 (0.1
H/H 1.10 (0.29- 1.80) 0.17 (0.0
Asymptomatic malaria R/R 3.43 (0.80- 7.30) 7.12 (4.90
R/H 3.75 (0.90- 6.42) 6.67 (4.95
H/H 2.67 (0.80- 5.64) 5.48 (4.91
P value* 0.661 0.02
*P value was derived from Kruskal-Wallis test (nonparametric).cellular branches of the immune system [48]. In the
present study, the FcγRIIa genotype was related to PAM
in Saudi women. FcγRIIa-R/R131 and R131 genotype
were associated with ASM compared to MFC. However,
FcγRIIa-H/H131 genotype and H131 allele had lower
frequency in ASM compared to MFC. A previous study
in western Kenya suggested that FcγRIIa- H/H131 geno-
type was associated with enhanced susceptibility to pla-
cental malaria in HIV positive women but not in HIV
negative women [25]. Studies in different settings
suggested that the FcγRIIa-R/R131 genotype protects
against high levels of parasitaemia, whereas the FcγRIIa-
H/H131 genotype was associated with susceptibility to
severe malaria with high parasite burden [49-51]. An
additional study in Sudan showed an association be-
tween FcγRIIa-R/R131 and severe malaria [20].
The present study was undertaken to examine the re-
lationship between polymorphism in the gene for pri-
mary cellular IgG receptor, FcγRIIa and PAM. This
study has provided evidence that the high levels of IgG
subclasses are associated with FcγRIIa-R/R131 genotype
among ASM women in southern Saudi. The results are
in contrast with a study in western Kenya which de-
scribed evidence that the IgG2-binding FcγRIIa-H/H131
genotype is associated with increased susceptibility to
placental malaria in HIV-positive women [25].
Although, the FcγRIIa are important molecules in mal-
aria outcome; several studies have attempted to associate
mutations in these genes with increased susceptibility to
developing different forms of malaria. However, the-1) antibodies responses and distribution of FcγRIIa 131
1 IgG2 IgG3 IgG4
(Range) Median (Range) Median (Range) Median (Range)
6- 1.41) 0.10 (0.02- 0.13) 0.15 (0.12- 0.62) 0.02 (0.02- 0.03)
0- 1.55) 0.04 (0.02- 0.13) 0.46 (0.01- 0.65) 0.01 (0.01- 0.56)
5- 1.58) 0.04 (0.02- 0.16) 0.50 (0.01- 0.65) 0.01 (0.01- 0.56)
- 32.89) 2.79 (1.84- 6.10) 12.50 (7.52- 46.00) 0.86 (0.01- 3.24)
- 21.22) 2.62 (1.98- 5.60) 10.65 (7.97- 37.58) 0.73 (0.59- 1.88)
- 11.51) 2.21 (1.95- 3.64) 8.40 (7.78- 20.99) 0.59 (0.01- 1.70)
1 0.021 <0.001 0.006
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determined. This confliction may be due to differences
in the degrees of malarial endemicity, and genetic back-
ground of the individual as well as the differences in the
study designs.Conclusions
Taken together, this study revealed that the ASM pa-
tients showed higher anti-malarial IgG and IgG subclass
antibody levels when compared to the MFC. Furthermore,
FcγRIIa-R/R131 genotype and R131 allele were associated
with ASM patients. However, the FcγRIIa-H/H131 geno-
type is associated with higher levels of anti-malarial IgG
subclass. Thus, the higher IgG subclass antibody levels
seen in the ASM may be due to the relatively high preva-
lence of the individuals carrying the H/H131 genotype in
this study group. Expectedly, the result of the present
study suggests that the magnitude and the quality of anti-
malarial humoral response is not the only key element
for relative reduction in malaria infection in the ASM
group. Further studies are needed to elucidate if the
FcγRIIa-R/H131 polymorphism is a contributing factor to the
differential susceptibility to malaria seen in different groups.Competing interests
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